Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 10/20 | 1.00 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.98 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.98 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.98 |
| ▸ | OGT | O15294 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441461 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL29397191 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL1521296 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL29396726 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL16138527 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL23344493 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL12377962 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL14281873 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL20718791 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT | |
| SCHEMBL19315974 | 1.00 | P2RY14 (1.00) | P2RY14P2RY6P2RY2P2RY4OGT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | claimed |
| US-20250345420-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | UNIV CORNELL (US) | 2025-11-13 | — | — | US | claimed |
| EP-4531917-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | Cornell University (US) | 2025-04-09 | — | — | EP | claimed |
| CN-119677538-A | Cancer immunotherapy for promotion of hyperacute rejection | 康奈尔大学 | 2025-03-21 | — | — | CN | claimed |
| WO-2025019764-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | MATTERWORKS INC (US) | 2025-01-23 | — | — | WO | claimed |
| EP-4437319-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | Matterworks Inc (US) | 2024-10-02 | — | — | EP | claimed |
| US-20240000959-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | CORNELL UNIVERSITY | 2024-01-04 | — | — | US | claimed |
| CN-117320707-A | Cancer immunotherapy for promotion of hyperacute rejection | 康奈尔大学 | 2023-12-29 | — | — | CN | claimed |
| WO-2023235727-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | CORNELL UNIVERSITY (US) | 2023-12-07 | — | — | WO | claimed |
| EP-4251147-A2 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | Cornell University (US) | 2023-10-04 | — | — | EP | claimed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | claimed |
| WO-2022115775-A2 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | CORNELL UNIVERSITY (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260097055-A1 | COGNITION | CULLIS HILL SYDNEY DAVID (AU) | 2026-04-09 | — | — | US | disclosed |
| US-12521409-B2 | Cognition | CULLIS HILL SYDNEY DAVID (AU) | 2026-01-13 | — | — | US | disclosed |
| US-20250345420-A1 | CANCER IMMUNOTHERAPIES TO PROMOTE HYPERACUTE REJECTION | UNIV CORNELL (US) | 2025-11-13 | — | — | US | disclosed |
| EP-3976820-A1 | METHODS OF DETECTING SPATIAL HETEROGENEITY OF A BIOLOGICAL SAMPLE | 10X Genomics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-9187546-B2 | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants | NOVO NORDISK A/S (DK) | 2015-11-17 | — | — | US | disclosed |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | NOVO NORDISK AS (DK) | 2015-04-23 | — | — | US | disclosed |
| US-8633157-B2 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097055-A1 | COGNITION | FUT5, GLA, CSGALNACT1 | P2RY14 2265/4885P2RY6 1484/4885P2RY2 1417/4885 |
| US-20150111245-A1 | GLYCOPEGYLATED FOLLICLE STIMULATING HORMONE | FSHR, SHBG, GNRHR | P2RY14 4654/4885P2RY6 4541/4885P2RY2 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.